1040 / 1983
Shapiro et al. Lancet Oncol 2015
Median follow-up for surviving patients: 84.1 months
(HR 0.68 [95% CI 0.53-0.88]; log-rank p=0.003)
SCC: HR 0.48 [95% CI 0.28-0.83]; log-rank p=0.008
AC: HR 0.73 [95% CI 0.55-0.98]; log-rank p=0.038
Neoadjuvant chemoradiation in esophageal cancer: CROSS trial
EBRO
2017